Newer oral anticoagulant agents: A new era in medicine

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


After a gap of almost 60 years following the development of warfarin, 2 new categories of oral anticoagulant agents have been approved for clinical use - the direct thrombin inhibitors and factor Xa inhibitors. These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin. The clinical community is looking forward to the widespread usage of these agents but there is also some apprehension regarding bleeding risks, non-availability of specific reversal strategies and lack of specific monitoring parameters. This review article will attempt to educate the reader about three representative drugs from these classes: Dabigatran, Rivaroxaban and Apixaban. We will discuss the historical perspective to the development of these drugs, available research data and pharmacology of these agents. The best strategies for monitoring and reversal of these drugs in special situations will also be touched upon.

Original languageEnglish (US)
Pages (from-to)158-165
Number of pages8
JournalCurrent Cardiology Reviews
Issue number2
StatePublished - 2012


  • Acute coronary syndrome
  • Apixaban
  • Atrial fibrillation
  • Dabigatran
  • Deep venous thrombosis
  • Pulmonary embolism
  • Rivaroxaban
  • Venous thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Newer oral anticoagulant agents: A new era in medicine'. Together they form a unique fingerprint.

Cite this